Next Article in Journal / Special Issue
Preface to Special Issue on ‘Cytochrome P450 Variation in Pharmacogenomics’
Previous Article in Journal
Willingness to Participate in a National Precision Medicine Cohort: Attitudes of Chronic Kidney Disease Patients at a Cleveland Public Hospital
Previous Article in Special Issue
Ten Years’ Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics
Article Menu

Export Article

Open AccessFeature PaperReview
J. Pers. Med. 2018, 8(3), 22; https://doi.org/10.3390/jpm8030022

Warfarin: The End or the End of One Size Fits All Therapy?

Department of Molecular and Clinical Pharmacology, Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool L69 3GL, UK
Received: 7 May 2018 / Revised: 24 June 2018 / Accepted: 25 June 2018 / Published: 28 June 2018
(This article belongs to the Special Issue Cytochrome P450 Variation in Pharmacogenomics)
View Full-Text   |   Download PDF [697 KB, uploaded 28 June 2018]   |  

Abstract

Oral anticoagulants are required for both treatment and prophylaxis in many different diseases. Clinicians and patients now have a choice of oral anticoagulants, including the vitamin K antagonists (of which warfarin is the most widely used and is used as the exemplar in this paper), and direct oral anticoagulants (DOACs: dabigatran, apixaban, rivaroxaban, and edoxaban). This paper explores the recent advances and controversies in oral anticoagulation. While some commentators may favour a complete switchover to DOACs, this paper argues that warfarin still has a place in therapy, and a stratified approach that enables the correct choice of both drug and dose would improve both patient outcomes and affordability. View Full-Text
Keywords: warfarin; vitamin K antagonists; direct oral anticoagulants; dabigatran; rivaroxaban; apixaban; edoxaban; pharmacogenomics; personalized medicine; therapeutic drug monitoring warfarin; vitamin K antagonists; direct oral anticoagulants; dabigatran; rivaroxaban; apixaban; edoxaban; pharmacogenomics; personalized medicine; therapeutic drug monitoring
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Pirmohamed, M. Warfarin: The End or the End of One Size Fits All Therapy? J. Pers. Med. 2018, 8, 22.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top